摘要
目的:探讨放射性粒子125I联合顺铂(DDP)植入H22肝癌组织后,观察肝癌的病理变化。方法:分别把125 I,DDP和两者联合植入荷H22肝癌小鼠瘤体内28 d,观察肿瘤生长,应用光镜和电子显微镜观察H22肝癌细胞的变化情况。结果:125 I,DDP植入肿瘤组织后,瘤体生长受到一定的影响;两者合用后致肿瘤生长变慢且出现变性坏死。镜下观察:125 I,DDP两组可见癌细胞形态不规则,有坏死的癌细胞,周围组织有大量淋巴细胞浸润;125I+DDP组癌组织以癌细胞坏死为特征;电镜下125I,DDP两组核膜完整,染色质分布均匀,核仁浓缩或碎裂,凋亡小体形成,粗面内质网结构松散、脱粒、滑面内质网增多,其间有较多凋亡的癌细胞,并有多个凋亡细胞聚集;而125I+DDP组为坏死或不完全坏死的癌细胞为主,其间也有凋亡的癌细胞。结论:放射性粒子125I与DDP组织间植入可导致肿瘤变性、死亡,还可诱导肿瘤细胞凋亡,是一种简便易行,安全有效的新治疗。
Objective:To investigate the pathological change of H22 hepatoma induced by radioactive particle125I combine with cisplatin(DDP).Method:125I,Cisplatin(DDP) and 125I combined with DDP were implanted into the mice H22 hepatoma,individually.After 28 days,the tumor growth was observed,and the pathological change in the cells were investigated by optical microscope and electron microscope.Result:After125I,DDP were implanted into the mice H22 hepatoma,the tumor growth showed fast at first phase and then became slow;125I combined with DDP made the tumor growth slower with cell degeneration and necrosis.Under the optical microscope,cells of125I group and DDP group had a irregular shape,part of cells showed necrosis and surrounding tissue cells had lots of lymphocytes.But the characteristics of125I combined with DDP was cells necrosis.Under the electron microscope,the nuclear membrane was complete,chromatin distributed uniform,nucleolus was concentrated or fragmentated and the apoptotic bodies were form.The configuration of rough endoplasmic reticulum was loosening and degranulated,with increasing endoplasmic reticulum,which had more apoptosis of cancer cells,and had more apoptotic cells aggregated in the125I group and DDP group.But the125I combined with DDP group was with necrosis or incomplete necrotic cells mainly,which also had the apoptosis cancer cells.Conclusion:The interstitial implant of radioactive seed125I induces hepatoma cells apoptosis.125I combined with DDP induces apoptosis,cell degeneration and necrosis.
出处
《中国实验方剂学杂志》
CAS
北大核心
2011年第11期223-226,共4页
Chinese Journal of Experimental Traditional Medical Formulae
基金
广西科技厅基金项目(桂科基0575064
桂科攻10124001A-3)